EFDID: 169952EFD: View Filing

Issuer: Kalytera Therapeutics, Inc. (0001639643) - D

Accession: 0001639643-16-000004 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001639643
  • Entity Name:
    Kalytera Therapeutics, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2014)
  • Address:
    500 S. Sepulveda Blvd., Suite 212
    Manhattan Beach, CA 90266
  • Persons:
    Related Persons 7
    Seth Yakatan
    Executive Officer, Director 
    Chief Executive Officer
    David Stefansky
    Director 
    Chairman of the Board
    Farrell Robert
    Executive Officer, Director 
    President, Chief Operating Officer and Chief Financial Officer
    Victoria Rudman
    Executive Officer 
    Secretary
    Ronald Erickson
    Director
    Jerome Zeldis
    Director
    Jeffrey Paley
    Director
EDGAR: Offering Information
  • Accession Date:
    08/03/2016
  • First Sale Date:
    07/19/2016
  • Offering Amount:
    $2,400,000
  • Amount Sold:
    $250,750
  • Amount Remaining:
    $2,149,250
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
  • Sales Clarification:
    Total offering amount includes $400,000 to cover any over-allotments over the maximum offering amount of $2,000,000.
EFD: Current State Notices

No State Notices found in EFD

EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
Newbridge Securities 0052 Dawson James Securities, Inc. 130645 FL, NY
Newbridge Securities 0052 Cova Capital Partners LLC 109761 FL, NY
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Kalytera Therapeutics, Inc./s/ Seth YakatanSeth YakatanChief Executive Officer2016-08-02